Sol-Gel Technologies

Historical price data

Sol-Gel Technologies' mission is to develop and commercialize advanced topical dermatological therapies using its patented Sol-Gel microencapsulation platform. Its key achievement is the FDA approval and launch of TWYNEO® for acne vulgaris, marking its transition to a commercial entity. The company's strategy combines proprietary development of its pipeline with strategic out-licensing to established dermatology players for commercialization. With a pipeline of 15 candidates targeting acne, rosacea, psoriasis, and other conditions, Sol-Gel aims to build a portfolio of differentiated products in the growing medical dermatology market.

Proprietary silica-based microencapsulation technology that entraps drug molecules in an inert silica matrix, enabling stabilization of incompatible actives, controlled release, and improved tolerability for topical dermatological products.

Competes against large dermatology pharma and biotechs with novel biological agents. Sol-Gel's differentiation lies in its drug delivery platform, aiming to improve established therapies rather than discover new targets, which creates both a niche opportunity and a challenge in demonstrating superior clinical value.